199 related articles for article (PubMed ID: 33374439)
21. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases.
Yemelyanova A; Ji H; Shih IeM; Wang TL; Wu LS; Ronnett BM
Am J Surg Pathol; 2009 Oct; 33(10):1504-14. PubMed ID: 19623034
[TBL] [Abstract][Full Text] [Related]
22. Laminin C1 expression by uterine carcinoma cells is associated with tumor progression.
Kashima H; Wu RC; Wang Y; Sinno AK; Miyamoto T; Shiozawa T; Wang TL; Fader AN; Shih IeM
Gynecol Oncol; 2015 Nov; 139(2):338-44. PubMed ID: 26343160
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical characterization of endometrial carcinomas: endometrioid, serous and clear cell adenocarcinomas in association with genetic analysis.
Yasuda M
J Obstet Gynaecol Res; 2014 Dec; 40(12):2167-76. PubMed ID: 25363801
[TBL] [Abstract][Full Text] [Related]
24. High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes.
Alkushi A; Köbel M; Kalloger SE; Gilks CB
Int J Gynecol Pathol; 2010 Jul; 29(4):343-50. PubMed ID: 20567148
[TBL] [Abstract][Full Text] [Related]
25. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma.
Zheng W; Yi X; Fadare O; Liang SX; Martel M; Schwartz PE; Jiang Z
Am J Surg Pathol; 2008 Feb; 32(2):304-15. PubMed ID: 18223334
[TBL] [Abstract][Full Text] [Related]
26. Histopathological features of endometrial carcinomas associated with POLE mutations: implications for decisions about adjuvant therapy.
Bakhsh S; Kinloch M; Hoang LN; Soslow RA; Köbel M; Lee CH; McAlpine JN; McConechy MK; Gilks CB
Histopathology; 2016 May; 68(6):916-24. PubMed ID: 26416160
[TBL] [Abstract][Full Text] [Related]
27. Integrated microRNA and mRNA transcriptome sequencing reveals the potential roles of miRNAs in stage I endometrioid endometrial carcinoma.
Xiong H; Li Q; Liu S; Wang F; Xiong Z; Chen J; Chen H; Yang Y; Tan X; Luo Q; Peng J; Xiao G; Jiang Q
PLoS One; 2014; 9(10):e110163. PubMed ID: 25329664
[TBL] [Abstract][Full Text] [Related]
28. [MicroRNA expression signature profile and its clinical significance in endometrioid carcinoma].
Wang Y; Adila S; Zhang X; Dong Y; Li W; Zhou M; Li T
Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):88-94. PubMed ID: 24742567
[TBL] [Abstract][Full Text] [Related]
29. Dysregulated microRNAs and their predicted targets associated with endometrioid endometrial adenocarcinoma in Hong Kong women.
Chung TK; Cheung TH; Huen NY; Wong KW; Lo KW; Yim SF; Siu NS; Wong YM; Tsang PT; Pang MW; Yu MY; To KF; Mok SC; Wang VW; Li C; Cheung AY; Doran G; Birrer MJ; Smith DI; Wong YF
Int J Cancer; 2009 Mar; 124(6):1358-65. PubMed ID: 19065659
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical characterization of prototypical endometrial clear cell carcinoma--diagnostic utility of HNF-1β and oestrogen receptor.
Hoang LN; Han G; McConechy M; Lau S; Chow C; Gilks CB; Huntsman DG; Köbel M; Lee CH
Histopathology; 2014 Mar; 64(4):585-96. PubMed ID: 24103020
[TBL] [Abstract][Full Text] [Related]
31. A TrkB-STAT3-miR-204-5p regulatory circuitry controls proliferation and invasion of endometrial carcinoma cells.
Bao W; Wang HH; Tian FJ; He XY; Qiu MT; Wang JY; Zhang HJ; Wang LH; Wan XP
Mol Cancer; 2013 Dec; 12():155. PubMed ID: 24321270
[TBL] [Abstract][Full Text] [Related]
32. Down-regulation of miR-145 and miR-143 might be associated with DNA methyltransferase 3B overexpression and worse prognosis in endometrioid carcinomas.
Zhang X; Dong Y; Ti H; Zhao J; Wang Y; Li T; Zhang B
Hum Pathol; 2013 Nov; 44(11):2571-80. PubMed ID: 24071015
[TBL] [Abstract][Full Text] [Related]
33. Promoter Methylation-mediated Silencing of the MiR-192-5p Promotes Endometrial Cancer Progression by Targeting ALX1.
Ni J; Tian W; Liang S; Wang H; Ren Y
Int J Med Sci; 2021; 18(12):2510-2520. PubMed ID: 34104082
[No Abstract] [Full Text] [Related]
34. MiRNAs in endometrioid endometrial cancer metastatic loci derived from positive lymph nodes.
Wilczynski M; Senderowska D; Krawczyk T; Szymanska B; Malinowski A
Acta Obstet Gynecol Scand; 2020 Aug; 99(8):1085-1091. PubMed ID: 32100871
[TBL] [Abstract][Full Text] [Related]
35. Deregulation of miR-100, miR-99a and miR-199b in tissues and plasma coexists with increased expression of mTOR kinase in endometrioid endometrial carcinoma.
Torres A; Torres K; Pesci A; Ceccaroni M; Paszkowski T; Cassandrini P; Zamboni G; Maciejewski R
BMC Cancer; 2012 Aug; 12():369. PubMed ID: 22920721
[TBL] [Abstract][Full Text] [Related]
36. Molecular Genetics of Endometrial Carcinoma.
Bell DW; Ellenson LH
Annu Rev Pathol; 2019 Jan; 14():339-367. PubMed ID: 30332563
[TBL] [Abstract][Full Text] [Related]
37. A novel miR-193a-5p-YY1-APC regulatory axis in human endometrioid endometrial adenocarcinoma.
Yang Y; Zhou L; Lu L; Wang L; Li X; Jiang P; Chan LK; Zhang T; Yu J; Kwong J; Cheung TH; Chung T; Mak K; Sun H; Wang H
Oncogene; 2013 Jul; 32(29):3432-42. PubMed ID: 22907428
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemical and genetic profiles of endometrioid endometrial carcinoma arising from atrophic endometrium.
Geels YP; van der Putten LJ; van Tilborg AA; Lurkin I; Zwarthoff EC; Pijnenborg JM; van den Berg-van Erp SH; Snijders MP; Bulten J; Visscher DW; Dowdy SC; Massuger LF
Gynecol Oncol; 2015 May; 137(2):245-51. PubMed ID: 25773202
[TBL] [Abstract][Full Text] [Related]
39. Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: diagnostic significance and clinicopathologic correlations.
Li C; Zota V; Woda BA; Rock KL; Fraire AE; Jiang Z; Lu D; Xu B; Dresser K; Lutman CV; Fischer AH
Mod Pathol; 2007 Dec; 20(12):1263-8. PubMed ID: 17885673
[TBL] [Abstract][Full Text] [Related]
40. MiR-29a-5p inhibits proliferation and invasion and induces apoptosis in endometrial carcinoma via targeting TPX2.
Jiang T; Sui D; You D; Yao S; Zhang L; Wang Y; Zhao J; Zhang Y
Cell Cycle; 2018; 17(10):1268-1278. PubMed ID: 29888640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
